Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 9:24 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1033–1056 of 1,229 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: TBL 12 Clear all

Conditions: Healthy
Interventions: lomitapide, EE/norgestimate; Drug
Lead sponsor: Aegerion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Melanoma (Skin Cancer), HER2-low Hormone Receptor Positive Breast Cancer
Interventions: AMXT 1501 Dicaprate, DFMO, Fulvestrant, Capivasertib, Pembrolizumab; Drug
Lead sponsor: Aminex Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 20
States / cities: Tucson, Arizona • La Jolla, California • Los Angeles, California + 15 more

Conditions: Breast Cancer Female, Breast Cancer, Breast Cancer Metastatic, Estrogen Receptor-positive Breast Cancer, HER2-positive Breast Cancer, Stage IV Breast Cancer
Interventions: Nab-Paclitaxel, Paclitaxel, Docetaxel, Phesgo, T-DM1, Pertuzumab, Trastuzumab Deruxtecan, Trastuzumab Subcutaneous Subcutaneous, Tucatinib, Trastuzumab; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2033
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Cystic Fibrosis
Interventions: Lumacaftor, Ivacaftor, Ciprofloxacin, Itraconazole, Rifampin; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2013
U.S. locations: 1
States / cities: Evansville, Indiana

Conditions: Diarrhea
Interventions: Calcium Carbonate, nelfinavir, lamivudine, loperamide, Calcium carbonate not administered, lamivudine + zidovudine; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003
U.S. locations: 6
States / cities: Birmingham, Alabama • Fort Lauderdale, Florida • New York, New York + 3 more

Conditions: Hepatitis C, Chronic
Interventions: Epclusa (SOF/VEL), Standard of care, Fibroscan® 430 Mini Plus; Drug · Device
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 64 Years
Enrollment: 87 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Stress Disorders, Post-Traumatic
Interventions: Brexpiprazole, Sertraline, Brexpiprazole Matching Placebo, Sertraline Matching Placebo; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 336 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 54
States / cities: Tuscaloosa, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 48 more

Conditions: Cognitive Dysfunction, Memory Impairment
Interventions: Donepezil 5 mg, Placebo; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 75 Years · Female only
Enrollment: 276 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 278
States / cities: Anaheim, California • Antioch, California • Baldwin Park, California + 206 more

Conditions: Primary Generalized Epilepsy
Interventions: Cenobamate, Placebo; Drug
Lead sponsor: SK Life Science, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 169 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 43
States / cities: Phoenix, Arizona • Tuscon, Arizona • Fresno, California + 37 more

Conditions: HIV Infection
Interventions: ritonavir, fosamprenavir; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 2 Years to 18 Years
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2008
U.S. locations: 17
States / cities: Birmingham, Alabama • Los Angeles, California • Jacksonville, Florida + 13 more

Conditions: Heart Failure
Interventions: Empagliflozin, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 312 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 41
States / cities: Mobile, Alabama • Saraland, Alabama • Huntington Beach, California + 37 more

Conditions: Drug Interaction Study
Interventions: Pacritinib, Clarithromycin, Pacritinib and Clarithromycin; Drug
Lead sponsor: CTI BioPharma; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Stress Disorders, Post-Traumatic
Interventions: Trauma-Focused Cognitive Behavioral Therapy, Sertraline Pill, Placebo Oral Tablet; Behavioral · Drug
Lead sponsor: Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute); Other
Eligibility: 10 Years to 17 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2006
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Infection, Human Immunodeficiency Virus
Interventions: Ortho-Cyclen, Dolutegravir, Placebo; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Hepatitis C Virus
Interventions: Pegylated-Interferon-lambda, Ribavirin, Daclatasvir; Biological · Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 4
States / cities: Palo Alto, California • Chicago, Illinois • Philadelphia, Pennsylvania + 1 more

Conditions: Human Immunodeficiency Virus
Interventions: Maraviroc; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 2 Years to 18 Years
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2023
U.S. locations: 18
States / cities: Los Angeles, California • Orange, California • Wilmington, Delaware + 10 more

Conditions: Antipsychotic Induced Weight Gain, Non-alcoholic Steatohepatitis (NASH)
Interventions: Miricorilant, Fluvoxamine; Drug
Lead sponsor: Corcept Therapeutics; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Hepatitis C Virus Infection
Interventions: SOF/VEL; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 25
States / cities: Long Beach, California • Los Angeles, California • Palo Alto, California + 18 more

Conditions: Urgency Urinary Incontinence
Interventions: Trospium, Placebo oral tablet; Drug
Lead sponsor: Becky Clarkson; Other
Eligibility: 60 Years and older · Female only
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Fibromyalgia
Interventions: TNX-102 SL, Placebo SL Tablet; Drug
Lead sponsor: Tonix Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 514 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 36
States / cities: Birmingham, Alabama • Phoenix, Arizona • Oceanside, California + 33 more

Conditions: Juvenile Idiopathic Arthritis (JIA)
Interventions: VIMOVO 250/20, VIMOVO 375/20, VIMOVO 500/20; Drug
Lead sponsor: Amgen; Industry
Eligibility: 12 Years to 16 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 17
States / cities: Little Rock, Arkansas • San Francisco, California • Aurora, Colorado + 14 more

Conditions: Autism Spectrum Disorder
Interventions: ML-004 (IR)/(ER) tablet; Drug
Lead sponsor: MapLight Therapeutics; Industry
Eligibility: 12 Years to 46 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 18
States / cities: Dothan, Alabama • Phoenix, Arizona • Glendale, California + 15 more

Conditions: Hepatitis C
Interventions: DCV/ASV/BMS-791325, Ribavirin, Sofosbuvir, Peginterferon α-2a; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: Not listed
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 7
States / cities: Rialto, California • Chicago, Illinois • Indianapolis, Indiana + 2 more

Conditions: Eosinophilic Esophagitis
Interventions: Famotidine, Loratadine, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Jacksonville, Florida

Search by objective public record fields.

Evaluate the Effect of Ethinyl Estradiol/Norgestimate on the Pharmacokinetics of Lomitapide in Healthy Female Subjects

Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors

The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer

A Phase 1 Study to Examine the Drug-Drug Interaction of Ciprofloxacin, Itraconazole, and Rifampin on the Combination of Lumacaftor With Ivacaftor in Healthy Adult Subjects

A Study to Determine Effective Prophylaxis and Treatment of Nelfinavir-Associated Diarrhea

The No One Waits Study: Acceptability and Feasibility of Community-based Point-of-diagnosis HCV Treatment Study

A Study of Flexible Dose Brexpiprazole as Monotherapy or Combination Therapy in the Treatment of Adults With Post-traumatic Stress Disorder (PTSD)

Phase 3 Randomized Placebo Controlled Clinical Trial of Donepezil

Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Cenobamate Adjunctive Therapy in PGTC Seizures

A Clinical Study Of An Investigational Regimen Including Marketed HIV Drugs In HIV-1 Pediatric Subjects Ages 2-18 Years

This Study Tests Empagliflozin in Patients With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF). The Study Looks at How Far Patients Can Walk in 6 Minutes and at Their Heart Failure Symptoms

To Evaluate the Effect of Clarithromycin on the Systemic Exposure of Pacritinib in Healthy Subjects

Pharmacologic Treatment of PTSD in Sexually Abused Children

Drug Interaction Study Between Dolutegravir and an Oral Contraceptive Containing Norgestimate and Ethinylestradiol

Safety and Efficacy Study in Subjects With Chronic HCV and Underlying Hemophilia

An Open Label Pharmacokinetic, Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy For The Treatment Of HIV-1 Infected, CCR5 -Tropic Children

Study to Evaluate the Effects of a Cytochrome P450 2C19 Inhibitor on the Pharmacokinetics of Miricorilant

Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection

Investigation of Brain Mechanisms Involved in Urgency Urinary Incontinence

A Phase 3 Study To Evaluate The Efficacy And Safety Of TNX-102 SL In Patients With Fibromyalgia

A Safety Study of VIMOVO in Adolescents With Juvenile Idiopathic Arthritis (JIA)

ML-004 Open-Label Extension Study in Adults and Adolescents With Autism Spectrum Disorders (ASD)

Short Duration Combination Therapy With Daclatasvir, Asunaprevir, BMS-791325 and Sofosbuvir in Subjects Infected With Chronic Hepatitis-C (FOURward Study)

Antihistamines in Eosinophilic Esophagitis